gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-5-16-24gastro-j-646Research ArticleОБЗОРЫREVIEWSФармакотерапия фиброза печени в исходе неалкогольного стеатогепатитаDrug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosishttps://orcid.org/0000-0001-9809-8015ГарбузенкоД. В.GarbuzenkoD. V.

Гарбузенко Дмитрий Викторович — доктор медицинских наук, профессор кафедры факультетской хирургии

454092, г. Челябинск, ул. Воровского, д. 64

Dmitry V. Garbuzenko — Dr. Sci. (Med.), Prof., Chair of Faculty Surgery

454092, Chelyabinsk, Vorovskogo str., 64

garb@inbox.ruГБОУ ВПО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSouth Ural State Medical UniversityRussian Federation2021020120223151624Copyright © Гарбузенко Д.В., 20222022Гарбузенко Д.В.Garbuzenko D.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/646Цель обзора

Цель обзора: описать современное состояние проблемы фармакотерапии ассоциированного с неалкогольным стеатогепатитом (НАСГ) фиброза печени.

Основные положения

Основные положения. В соответствии с текущими клиническими рекомендациями лечебные мероприятия при неалкогольной жировой болезни печени должны заключаться в изменении образа жизни, нормализации массы тела, специфической фармакотерапии ассоциированного с НАСГ фиброза печени и лечении связанных с метаболическим синдромом заболеваний. Несмотря на отсутствие утвержденных схем антифибротической терапии при НАСГ, существует ряд препаратов, которые в клинических испытаниях фазы 3 продемонстрировали адекватный профиль эффективности и безопасности у разных больных, включая пациентов с компенсированным циррозом печени. Это позволяет одобрить их для проверки и подтверждения практической пользы в клинических испытаниях фазы 4.

Заключение

Заключение. Учитывая, что развитие фиброза печени является неблагоприятным событием естественного течения неалкогольной жировой болезни печени, очевидно, что скорейшее внедрение и широкое применение методов антифибротической терапии улучшит результаты лечения НАСГ и позволит избежать связанных с ним осложнений.

Aim

Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.

Key points

Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver fibrosis-specific drug therapy and treatment for metabolic syndrome-related diseases. Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.

Conclusion

Conclusion. The understanding of liver fibrosis as an adverse natural consequence of non-alcoholic fatty liver disease clearly attests for an early introduction and wide use of antifibrotic therapy to improve NASH outcomes and avoid associated complications.

 

 

неалкогольный стеатогепатитфиброз печенифармакотерапияnon-alcoholic steatohepatitisliver fibrosisdrug therapyReferencesИвашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(2):24–42. DOI: 10.22416/1382-4376-2016-26-2-24-42Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Tikhonov I.N., Shirokova Ye.N., Buyeverov A.O., еt al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rus J gastroenterol, hepatol, coloproctol. 2016;26(2):24–42 (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-24-42Adams L.A., Roberts S.K., Strasser S.I., Mahady S.E., Powell E., Estes C., et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. J Gastroenterol Hepatol. 2020;35(9):1628–35. DOI: 10.1111/jgh.15009Adams L.A., Roberts S.K., Strasser S.I., Mahady S.E., Powell E., Estes C., et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. J Gastroenterol Hepatol. 2020;35(9):1628–35. DOI: 10.1111/jgh.15009Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(Suppl 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(Suppl 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004Wong V.W., Chan W.K., Chitturi S., Chawla Y., Dan Y.Y., Duseja A., et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. DOI: 10.1111/jgh.13857Wong V.W., Chan W.K., Chitturi S., Chawla Y., Dan Y.Y., Duseja A., et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. DOI: 10.1111/jgh.13857Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49(5):471–83. DOI: 10.1016/j.dld.2017.01.147Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49(5):471–83. DOI: 10.1016/j.dld.2017.01.147Leoni S., Tovoli F., Napoli L., Serio I., Ferri S., Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–73. DOI: 10.3748/wjg.v24.i30.3361Leoni S., Tovoli F., Napoli L., Serio I., Ferri S., Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–73. DOI: 10.3748/wjg.v24.i30.3361Roskilly A., Hicks A., Taylor E.J., Jones R., Parker R., Rowe I.A. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int. 2021;41(5):982–95. DOI: 10.1111/liv.14749Roskilly A., Hicks A., Taylor E.J., Jones R., Parker R., Rowe I.A. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int. 2021;41(5):982–95. DOI: 10.1111/liv.14749Mikolasevic I., Filipec-Kanizaj T., Mijic M., Jakopcic I., Milic S., Hrstic I., et al. Nonalcoholic fatty liver disease and liver transplantation — Where do we stand? World J Gastroenterol. 2018;24(14):1491–506. DOI: 10.3748/wjg.v24.i14.1491Mikolasevic I., Filipec-Kanizaj T., Mijic M., Jakopcic I., Milic S., Hrstic I., et al. Nonalcoholic fatty liver disease and liver transplantation — Where do we stand? World J Gastroenterol. 2018;24(14):1491–506. DOI: 10.3748/wjg.v24.i14.1491Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., Younossi I., et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580–9. DOI: 10.1016/j.cgh.2018.05.057Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., Younossi I., et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580–9. DOI: 10.1016/j.cgh.2018.05.057Anania F.A., Dimick-Santos L., Mehta R., Toerner J., Beitz J. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 2021;73(5):2023– 7. DOI: 10.1002/hep.31687Anania F.A., Dimick-Santos L., Mehta R., Toerner J., Beitz J. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 2021;73(5):2023– 7. DOI: 10.1002/hep.31687Longerich T., Schirmacher P. Determining the reliability of liver biopsies in NASH clinical studies. Nat Rev Gastroenterol Hepatol. 2020;17(11):653–4. DOI: 10.1038/s41575-020-00363-8Longerich T., Schirmacher P. Determining the reliability of liver biopsies in NASH clinical studies. Nat Rev Gastroenterol Hepatol. 2020;17(11):653–4. DOI: 10.1038/s41575-020-00363-8Cheah M.C., McCullough A.J., Goh G.B. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5(3):261–71. DOI: 10.14218/JCTH.2017.00009Cheah M.C., McCullough A.J., Goh G.B. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5(3):261–71. DOI: 10.14218/JCTH.2017.00009Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389– 97. DOI: 10.1053/j.gastro.2015.04.043Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389– 97. DOI: 10.1053/j.gastro.2015.04.043Brunt E.M., Kleiner D.E., Wilson L.A., Sanyal A.J., Neuschwander-Tetri B.A.; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019;70(2):522–31. DOI: 10.1002/hep.30418Brunt E.M., Kleiner D.E., Wilson L.A., Sanyal A.J., Neuschwander-Tetri B.A.; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019;70(2):522–31. DOI: 10.1002/hep.30418Kleiner D.E., Brunt E.M., Wilson L.A., Behling C., Guy C., Contos M., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2(10):e1912565. DOI: 10.1001/jamanetworkopen.2019.12565Kleiner D.E., Brunt E.M., Wilson L.A., Behling C., Guy C., Contos M., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2(10):e1912565. DOI: 10.1001/jamanetworkopen.2019.12565Campos-Murguía A., Ruiz-Margáin A., González-Regueiro J.A., Macías-Rodríguez R.U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(39):5919–43. DOI: 10.3748/wjg.v26.i39.5919Campos-Murguía A., Ruiz-Margáin A., González-Regueiro J.A., Macías-Rodríguez R.U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(39):5919–43. DOI: 10.3748/wjg.v26.i39.5919Galli F., Azzi A., Birringer M., Cook-Mills J.M., Eggersdorfer M., Frank J., et al. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017;102:16–36. DOI: 10.1016/j.freeradbiomed.2016.09.017Galli F., Azzi A., Birringer M., Cook-Mills J.M., Eggersdorfer M., Frank J., et al. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017;102:16–36. DOI: 10.1016/j.freeradbiomed.2016.09.017Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34. PMID: 26064294Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34. PMID: 26064294Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1056/NEJMoa0907929Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1056/NEJMoa0907929Lutchman G., Promrat K., Kleiner D.E., Heller T., Ghany M.G., Yanovski J.A., et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006;4(8):1048–52. DOI: 10.1016/j.cgh.2006.05.005Lutchman G., Promrat K., Kleiner D.E., Heller T., Ghany M.G., Yanovski J.A., et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006;4(8):1048–52. DOI: 10.1016/j.cgh.2006.05.005Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., OrtizLopez C., et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., OrtizLopez C., et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774Bril F., Kalavalapalli S., Clark V.C., Lomonaco R., Soldevila-Pico C., Liu I.C., et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–66. DOI: 10.1016/j.cgh.2017.12.001Bril F., Kalavalapalli S., Clark V.C., Lomonaco R., Soldevila-Pico C., Liu I.C., et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–66. DOI: 10.1016/j.cgh.2017.12.001Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607Lefebvre E., Moyle G., Reshef R., Richman L.P., Thompson M., Hong F., et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11(6):e0158156. DOI: 10.1371/journal.pone.0158156Lefebvre E., Moyle G., Reshef R., Richman L.P., Thompson M., Hong F., et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11(6):e0158156. DOI: 10.1371/journal.pone.0158156Friedman S.L., Ratziu V., Harrison S.A., Abdelmalek M.F., Aithal G.P., Caballeria J., et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–67. DOI: 10.1002/hep.29477Friedman S.L., Ratziu V., Harrison S.A., Abdelmalek M.F., Aithal G.P., Caballeria J., et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–67. DOI: 10.1002/hep.29477Ratziu V., Sanyal A., Harrison S.A., Wong V.W., Francque S., Goodman Z., et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020;72(3):892–905. DOI: 10.1002/hep.31108Ratziu V., Sanyal A., Harrison S.A., Wong V.W., Francque S., Goodman Z., et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020;72(3):892–905. DOI: 10.1002/hep.31108Markham A., Keam S.J. Obeticholic Acid: First Global Approval. Drugs. 2016;76(12):1221–6. DOI: 10.1007/s40265-016-0616-xMarkham A., Keam S.J. Obeticholic Acid: First Global Approval. Drugs. 2016;76(12):1221–6. DOI: 10.1007/s40265-016-0616-xMudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82. DOI: 10.1053/j.gastro.2013.05.042Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82. DOI: 10.1053/j.gastro.2013.05.042Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65. DOI: 10.1016/S0140-6736(14)61933-4Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65. DOI: 10.1016/S0140-6736(14)61933-4Chalasani N., Abdelmalek M.F., Loomba R., Kowdley K.V., McCullough A.J., Dasarathy S., et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39(5):924–32. DOI: 10.1111/liv.13974Chalasani N., Abdelmalek M.F., Loomba R., Kowdley K.V., McCullough A.J., Dasarathy S., et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39(5):924–32. DOI: 10.1111/liv.13974Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., et al.; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. DOI: 10.1016/S0140-6736(19)33041-7Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., et al.; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. DOI: 10.1016/S0140-6736(19)33041-7Loomba R., Sanyal A.J., Kowdley K.V., Terrault N., Chalasani N.P., Abdelmalek M.F., et al. Factors Associated with Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019;156(1):88–95. DOI: 10.1053/j.gastro.2018.09.021Loomba R., Sanyal A.J., Kowdley K.V., Terrault N., Chalasani N.P., Abdelmalek M.F., et al. Factors Associated with Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019;156(1):88–95. DOI: 10.1053/j.gastro.2018.09.021Li T., Chiang J.Y.L. Bile acid-based therapies for nonalcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surg Nutr. 2020;9(2):152–69. DOI: 10.21037/hbsn.2019.09.03Li T., Chiang J.Y.L. Bile acid-based therapies for nonalcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surg Nutr. 2020;9(2):152–69. DOI: 10.21037/hbsn.2019.09.03Harrison S.A., Rossi S.J., Paredes A.H., Trotter J.F., Bashir M.R., Guy C.D., et al. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis. Hepatology. 2020;71(4):1198– 212. DOI: 10.1002/hep.30590Harrison S.A., Rossi S.J., Paredes A.H., Trotter J.F., Bashir M.R., Guy C.D., et al. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis. Hepatology. 2020;71(4):1198– 212. DOI: 10.1002/hep.30590Harrison S.A., Neff G., Guy C.D., Bashir M.R., Paredes A.H., Frias J.P., et al. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology. 2021;160(1):219–31. DOI: 10.1053/j.gastro.2020.08.004Harrison S.A., Neff G., Guy C.D., Bashir M.R., Paredes A.H., Frias J.P., et al. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology. 2021;160(1):219–31. DOI: 10.1053/j.gastro.2020.08.004Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., et al.; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147–59. DOI: 10.3390/ijerph16224334Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., et al.; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147–59. DOI: 10.3390/ijerph16224334Shimizu M., Suzuki K., Kato K., Jojima T., Iijima T., Murohisa T., et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92. DOI: 10.1111/dom.13520Shimizu M., Suzuki K., Kato K., Jojima T., Iijima T., Murohisa T., et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92. DOI: 10.1111/dom.13520Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H., et al.; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549–59. DOI: 10.1002/hep.29514Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H., et al.; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549–59. DOI: 10.1002/hep.29514Harrison S.A., Wong V.W., Okanoue T., Bzowej N., Vuppalanchi R., Younes Z., et al.; STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39. DOI: 10.1016/j.jhep.2020.02.027Harrison S.A., Wong V.W., Okanoue T., Bzowej N., Vuppalanchi R., Younes Z., et al.; STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39. DOI: 10.1016/j.jhep.2020.02.027Loomba R., Kayali Z., Noureddin M., Ruane P., Lawitz E.J., Bennett M., et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(5):1463–73. DOI: 10.1053/j.gastro.2018.07.027Loomba R., Kayali Z., Noureddin M., Ruane P., Lawitz E.J., Bennett M., et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(5):1463–73. DOI: 10.1053/j.gastro.2018.07.027Loomba R., Noureddin M., Kowdley K.V., Kohli A., Sheikh A., Neff G., et al.; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021;73(2):625–43. DOI: 10.1002/hep.31622Loomba R., Noureddin M., Kowdley K.V., Kohli A., Sheikh A., Neff G., et al.; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021;73(2):625–43. DOI: 10.1002/hep.31622Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-XArmstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-XNewsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al.; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al.; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395Sharpton S.R., Maraj B., Harding-Theobald E., Vittinghoff E., Terrault N.A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139–49. DOI: 10.1093/ajcn/nqz042Sharpton S.R., Maraj B., Harding-Theobald E., Vittinghoff E., Terrault N.A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139–49. DOI: 10.1093/ajcn/nqz042Ratziu V., Guevara L., Safadi R., Poordad F., Fuster F., Flores-Figueroa J., et al. One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a steroyl CoA desaturase inhibitor, in patients with NASH. AASLD Liver Meeting, abstract LB-5, 2018.Ratziu V., Guevara L., Safadi R., Poordad F., Fuster F., Flores-Figueroa J., et al. One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a steroyl CoA desaturase inhibitor, in patients with NASH. AASLD Liver Meeting, abstract LB-5, 2018.Federico A., Dallio M., Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22(2):191. DOI: 10.3390/molecules22020191Federico A., Dallio M., Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22(2):191. DOI: 10.3390/molecules22020191Wah Kheong C., Nik Mustapha N.R., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940–9. DOI: 10.1016/j.cgh.2017.04.016Wah Kheong C., Nik Mustapha N.R., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940–9. DOI: 10.1016/j.cgh.2017.04.016

The authors declare that there are no conflicts of interest present.